Vapotherm, Inc. (NYSE:VAPO) CFO John Landry Purchases 135,000 Shares

Vapotherm, Inc. (NYSE:VAPOGet Rating) CFO John Landry acquired 135,000 shares of the business’s stock in a transaction dated Monday, November 28th. The stock was purchased at an average price of $0.78 per share, with a total value of $105,300.00. Following the acquisition, the chief financial officer now owns 303,074 shares of the company’s stock, valued at $236,397.72. The acquisition was disclosed in a filing with the SEC, which is available through this link.

Vapotherm Stock Up 51.7 %

NYSE:VAPO opened at $1.35 on Friday. Vapotherm, Inc. has a 1-year low of $0.46 and a 1-year high of $24.23. The company has a debt-to-equity ratio of 7.04, a current ratio of 3.88 and a quick ratio of 2.03. The business’s fifty day moving average price is $1.19 and its 200 day moving average price is $1.96.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of VAPO. Crow s Nest Holdings LP raised its position in Vapotherm by 180.1% during the first quarter. Crow s Nest Holdings LP now owns 1,544,850 shares of the company’s stock valued at $21,473,000 after buying an additional 993,350 shares during the period. Millennium Management LLC raised its position in Vapotherm by 1,598.6% during the second quarter. Millennium Management LLC now owns 985,992 shares of the company’s stock valued at $2,495,000 after buying an additional 927,944 shares during the period. Prescott General Partners LLC raised its position in Vapotherm by 45.0% during the first quarter. Prescott General Partners LLC now owns 2,557,243 shares of the company’s stock valued at $35,546,000 after buying an additional 793,504 shares during the period. Taylor Frigon Capital Management LLC raised its position in Vapotherm by 403.5% during the third quarter. Taylor Frigon Capital Management LLC now owns 933,600 shares of the company’s stock valued at $1,466,000 after buying an additional 748,176 shares during the period. Finally, Walleye Capital LLC acquired a new position in Vapotherm in the 2nd quarter worth about $379,000. 54.04% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have recently commented on VAPO. BTIG Research downgraded Vapotherm from a “buy” rating to a “neutral” rating in a report on Thursday, August 4th. William Blair downgraded Vapotherm from an “outperform” rating to a “market perform” rating in a report on Thursday, August 4th. Finally, Piper Sandler reduced their target price on Vapotherm from $2.50 to $2.00 and set an “underweight” rating for the company in a report on Thursday, August 4th. One analyst has rated the stock with a sell rating and four have assigned a hold rating to the company’s stock. According to data from MarketBeat, Vapotherm has a consensus rating of “Hold” and a consensus price target of $4.75.

About Vapotherm

(Get Rating)

Vapotherm, Inc, a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface.

Recommended Stories

Insider Buying and Selling by Quarter for Vapotherm (NYSE:VAPO)

Receive News & Ratings for Vapotherm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vapotherm and related companies with MarketBeat.com's FREE daily email newsletter.